Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
最新股票文章

黃金價格走勢分析2025:第三方目標與市場預測
黃金一直被視為經濟不確定時期的重要避險資產。隨著2025年受中央銀行政策轉向、通脹壓力變化以及地緣政治緊張局勢的影響,黃金在交易圈中仍然備受關注。
21:45, 28 4月 2025

MELANIA 幣($MELANIA)價格預測:第三方分析目標價揭曉
深入了解 MELANIA 加密貨幣的 2025 年及未來價格走勢,彙集第三方分析師與市場專家的專業洞見,為您提供全面的預測分析。
12:44, 22 1月 2025